Syros Pharmaceuticals Inc (NAS:SYRS)
$ 0.2159 0.013 (6.41%) Market Cap: 5.79 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 25/100

Syros Pharmaceuticals Inc to Announce Update on Selective CDK7 Inhibitor Portfolio Call Transcript

Oct 17, 2019 / 12:30PM GMT
Release Date Price: $69.6 (-31.09%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Syros Pharmaceuticals' conference call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Naomi Aoki, VP of Corporate Communications and Investor Relations. Please go ahead, ma'am.

Naomi Aoki
Syros Pharmaceuticals, Inc. - VP of Corporate Communications & IR

Thank you. This morning, we issued a press release providing an update on our portfolio of selection CDK7 inhibitors. This release, as well as the slides that we'll be reviewing on today's call, is available on the Investors and Media section of Syros' website at www.syros.com.

We will begin today's call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; and Dr. David Roth, our Chief Medical Officer. Then we will open the call for questions.

Dr. Eric Olson, our Chief Scientific Officer; Dr. Jeremy Springhorn, our Chief Business Officer; and Joe Ferra, our Chief Financial Officer, are also on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot